Trial Search Results

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Bristol-Myers Squibb

Collaborator: Nektar Therapeutics

Stanford Investigator(s):


  • Biological: NKTR-214
  • Biological: Nivolumab


Phase 3


Inclusion Criteria:

   - Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 (adults 18 years or
   older)/Lansky Performance Score ≥ 80% (minors ages 12-17 only)

   - Histologically confirmed stage III (unresectable) or stage IV melanoma

   - Treatment-naive participants (ie, no prior systemic anticancer therapy for
   unresectable or metastatic melanoma) with the exception of prior adjuvant and/or
   neoadjuvant treatment for melanoma with approved agents

Exclusion Criteria:

   - Active brain metastases or leptomeningeal metastases

   - Uveal melanoma

   - Participants with an active, known or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria apply

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Phuong Q Pham
Not Recruiting